$CVSI
CV Sciences, Inc. Stock $cvsi

$cvsi Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000151096422000033 Filed on April 04, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$4.969M	$20.05M	$5.199M
YoY Change	-4.42%	-17.93%	-44.26%
Cost Of Revenue	$3.359M	$11.43M	$2.978M
YoY Change	12.79%	-14.81%	-42.49%
Gross Profit	$1.610M	$8.616M	$2.221M
YoY Change	-27.51%	-21.74%	-46.48%
Gross Profit Margin	32.4%	42.98%	42.72%
Selling, General & Admin	$10.09M	$25.88M	$11.41M
YoY Change	-11.57%	-15.59%	11.96%
% of Gross Profit	626.65%	300.34%	513.69%
Research & Development	$364.0K	$1.185M
YoY Change		-59.73%
% of Gross Profit	22.61%	13.75%
Depreciation & Amortization	$407.0K	$1.153M	$243.0K
YoY Change	67.49%	32.22%	32.79%
% of Gross Profit	25.28%	13.38%	10.94%
Operating Expenses	$10.45M	$27.06M	$11.69M
YoY Change	-10.54%	-19.46%	1.67%
Operating Profit	-$8.843M	-$18.45M	-$9.464M
YoY Change	-6.56%	-18.35%	28.88%
Interest Expense	-$112.0K	-$140.0K	-$9.000K
YoY Change	1144.44%	1455.56%	-169.23%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$8.955M	-$15.64M	-$9.473M
YoY Change	-5.47%	-30.8%	29.24%
Income Tax	-$98.00K	-$87.00K	-$179.0K
% Of Pretax Income
Net Earnings	-$8.857M	-$15.55M	-$9.294M
YoY Change	-4.7%	-30.2%	39.01%
Net Earnings / Revenue	-178.25%	-77.58%	-178.77%
Basic Earnings Per Share		-$0.14
Diluted Earnings Per Share	-$80.54K	-$0.14	-$92.79K
COMMON SHARES
Basic Shares Outstanding	110.7M shares	107.8M shares	100.0M shares
Diluted Shares Outstanding		107.8M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.375M	$1.375M	$4.024M
YoY Change	-65.83%	-65.83%	-55.81%
Cash & Equivalents	$1.375M		$4.024M
Short-Term Investments
Other Short-Term Assets	$2.146M	$2.146M	$2.873M
YoY Change	-25.3%	-25.3%	-74.15%
Inventory	$8.624M	$8.624M	$8.840M
Prepaid Expenses	$2.146M		$2.372M
Receivables	$2.041M	$2.041M	$1.126M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.19M	$14.19M	$16.86M
YoY Change	-15.87%	-15.87%	-47.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.717M	$1.717M	$2.877M
YoY Change	-40.32%	-71.07%	-20.41%
Goodwill	$0.00		$2.788M
YoY Change	-100.0%		0.0%
Intangibles	$1.485M		$3.730M
YoY Change	-60.19%
Long-Term Investments
YoY Change
Other Assets	$678.0K	$678.0K	$1.310M
YoY Change	-48.24%	-48.24%	-9.15%
Total Long-Term Assets	$3.880M	$3.880M	$13.76M
YoY Change	-71.81%	-71.81%	-32.27%
TOTAL ASSETS
Total Short-Term Assets	$14.19M	$14.19M	$16.86M
Total Long-Term Assets	$3.880M	$3.880M	$13.76M
Total Assets	$18.07M	$18.07M	$30.63M
YoY Change	-41.01%	-41.01%	-41.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.624M	$2.624M	$1.677M
YoY Change	56.47%	56.47%	3.71%
Accrued Expenses	$10.92M	$10.92M	$9.805M
YoY Change	11.32%	4.1%	-9.68%
Deferred Revenue
YoY Change
Short-Term Debt	$612.0K	$612.0K	$0.00
YoY Change
Long-Term Debt Due	$310.0K	$310.0K	$2.174M
YoY Change	-85.74%	-85.74%
Total Short-Term Liabilities	$14.46M	$14.46M	$14.34M
YoY Change	0.87%	0.87%	8.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.453M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$1.453M
YoY Change	-100.0%	-100.0%	257.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.46M	$14.46M	$14.34M
Total Long-Term Liabilities	$0.00	$0.00	$1.453M
Total Liabilities	$14.52M	$14.52M	$19.41M
YoY Change	-25.19%	-25.19%	-17.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.48M		-$63.92M
YoY Change	24.33%		53.52%
Common Stock	$11.00K		$10.00K
YoY Change	10.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.543M	$3.543M	$11.21M
YoY Change
Total Liabilities & Shareholders Equity	$18.07M	$18.07M	$30.63M
YoY Change	-41.01%	-41.01%	-41.87%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$8.857M	-$15.55M	-$9.294M
YoY Change	-4.7%	-30.2%	39.01%
Depreciation, Depletion And Amortization	$407.0K	$1.153M	$243.0K
YoY Change	67.49%	32.22%	32.79%
Cash From Operating Activities	-$1.164M	-$7.500M	-$1.468M
YoY Change	-20.71%	2.74%	-68.27%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$35.00K	-$263.0K
YoY Change	-100.0%	-96.69%	6.91%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$35.00K	-$263.0K
YoY Change	-100.0%	-96.69%	6.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$4.407M
YoY Change		2183.42%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	879.0K	$4.370M	192.0K
YoY Change	357.81%	33.48%	-20.66%
NET CHANGE
Cash From Operating Activities	-1.164M	-$7.500M	-1.468M
Cash From Investing Activities	0.000	-$35.00K	-263.0K
Cash From Financing Activities	879.0K	$4.370M	192.0K
Net Change In Cash	-285.0K	-$3.150M	-1.539M
YoY Change	-81.48%	-38.03%	-66.76%
FREE CASH FLOW
Cash From Operating Activities	-$1.164M	-$7.500M	-$1.468M
Capital Expenditures	$0.00	$35.00K	-$263.0K
Free Cash Flow	-$1.164M	-$7.535M	-$1.205M
YoY Change	-3.4%	-9.84%	-72.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001510964
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2020	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	000-54677
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1677000	USD
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Registrant Name EntityRegistrantName	CV Sciences, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	80-0944974
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	10070 Barnes Canyon Road
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021	dei	City Area Code CityAreaCode	866
CY2021	dei	Local Phone Number LocalPhoneNumber	290-2157
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	41000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	122570186	shares
CY2021	dei	Auditor Firm AuditorFirmId	200
CY2021	dei	Auditor Name AuditorName	HASKELL & WHITE LLP
CY2021	dei	Auditor Location AuditorLocation	Irvine, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1375000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4024000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	501000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2041000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1126000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	8624000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8840000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2146000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2372000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	14186000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	16863000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1717000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2877000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3057000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1485000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3730000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	2788000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	678000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1310000	USD
CY2021Q4	us-gaap	Assets Assets	18066000	USD
CY2020Q4	us-gaap	Assets Assets	30625000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2624000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10915000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9805000	USD
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	612000	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	680000	USD
CY2021Q4	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	310000	USD
CY2020Q4	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	2174000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14461000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14336000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3467000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1453000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	62000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	157000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	14523000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	19413000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83007000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	75123000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79475000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63921000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3543000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	11212000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18066000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30625000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20048000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24429000	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	11432000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	13420000	USD
CY2021	us-gaap	Gross Profit GrossProfit	8616000	USD
CY2020	us-gaap	Gross Profit GrossProfit	11009000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1185000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2943000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25877000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30658000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	27062000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	33601000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-18446000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-22592000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2945000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-140000	USD
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15641000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22601000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-317000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15554000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22284000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107817000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107817000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99913000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99913000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	29147000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	175000	USD
CY2020	cvsi	Stock Issued During Period Value Equity Commitment StockIssuedDuringPeriodValueEquityCommitment	293000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3881000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22284000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	11212000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2021	cvsi	Stock Issued During Period Value Equity Commitment StockIssuedDuringPeriodValueEquityCommitment	4407000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	268000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3210000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15554000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3543000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15554000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-22284000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1153000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	872000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3210000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3881000	USD
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	100000	USD
CY2021	cvsi	Impairment Of Tax Receivable For Rsu Settlement ImpairmentOfTaxReceivableForRSUSettlement	0	USD
CY2020	cvsi	Impairment Of Tax Receivable For Rsu Settlement ImpairmentOfTaxReceivableForRSUSettlement	6229000	USD
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	72000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2945000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	972000	USD
CY2020	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	352000	USD
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	5033000	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-25000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-191000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	74000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	133000	USD
CY2021	cvsi	Noncash Lease Expense NoncashLeaseExpense	350000	USD
CY2020	cvsi	Noncash Lease Expense NoncashLeaseExpense	598000	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	94000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	264000	USD
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	247000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	134000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	989000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-918000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-216000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1703000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1045000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2959000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1644000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2118000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7485000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7300000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1057000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1057000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4407000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1000000	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	229000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	808000	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2021	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	2906000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	175000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4370000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3274000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3150000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5083000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4525000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9608000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1375000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4525000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	13000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	20000	USD
CY2021	cvsi	Purchase Of Insurance Through Issuance Of Note Payable PurchaseOfInsuranceThroughIssuanceOfNotePayable	397000	USD
CY2020	cvsi	Purchase Of Insurance Through Issuance Of Note Payable PurchaseOfInsuranceThroughIssuanceOfNotePayable	721000	USD
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	230000	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2021	cvsi	Right Of Use Asset Foregone In Exchange For Reduction In Operating Lease Liability RightOfUseAssetForegoneInExchangeForReductionInOperatingLeaseLiability	-2773000	USD
CY2020	cvsi	Right Of Use Asset Foregone In Exchange For Reduction In Operating Lease Liability RightOfUseAssetForegoneInExchangeForReductionInOperatingLeaseLiability	-4704000	USD
CY2021	us-gaap	Line Of Credit Facility Decrease Forgiveness1 LineOfCreditFacilityDecreaseForgiveness1	2945000	USD
CY2020	us-gaap	Line Of Credit Facility Decrease Forgiveness1 LineOfCreditFacilityDecreaseForgiveness1	0	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	15000	USD
CY2021	cvsi	Sale Of Property And Equipment In Exchange For Prepaid Expenses And Other And Inventory SaleOfPropertyAndEquipmentInExchangeForPrepaidExpensesAndOtherAndInventory	0	USD
CY2020	cvsi	Sale Of Property And Equipment In Exchange For Prepaid Expenses And Other And Inventory SaleOfPropertyAndEquipmentInExchangeForPrepaidExpensesAndOtherAndInventory	675000	USD
CY2021	cvsi	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	0	USD
CY2020	cvsi	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	108000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – The preparation of the financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results may differ from these estimates. Significant estimates include the valuation of intangible assets, inputs for valuing equity awards, and assumptions related to revenue recognition.</span>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – As of December 31, 2021, the Federal Deposit Insurance Corporation (“FDIC”) provided insurance coverage of up to $0.3 million per depositor per bank. The Company has not experienced any losses in such accounts and does not believe that the Company is exposed to significant risks from excess deposits. The Company’s cash balance in excess of FDIC limits totaled $1.0 million as of December 31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sources its raw materials from suppliers in Europe and the U.S. There was no other concentration of suppliers and no concentration of accounts receivable or revenue as of and for the years ended December 31, 2021 and 2020.</span></div>
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1000000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	500000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7500000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79500000	USD
CY2021Q4	us-gaap	Cash Cash	1400000	USD
CY2020Q4	us-gaap	Cash Cash	1600000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2400000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1375000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4024000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	501000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1375000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4525000	USD
CY2021	cvsi	Accounts Receivable Thresholdfor Determining Delinquent Account AccountsReceivableThresholdforDeterminingDelinquentAccount	P30D
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	500000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	600000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2800000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20048000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24429000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1300000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	1300000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4023000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4923000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1286000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	785000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3315000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3132000	USD
CY2021Q4	us-gaap	Inventory Gross InventoryGross	8624000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	8840000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5250000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5269000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3533000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2392000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1717000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2877000	USD
CY2021	us-gaap	Depreciation Depreciation	1200000	USD
CY2020	us-gaap	Depreciation Depreciation	800000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3907000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	177000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1485000	USD
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	2788000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2788000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3907000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	177000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3730000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	2788000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	2788000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2800000	USD
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	36000	USD
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	0	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	9023000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8324000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1892000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1481000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10915000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9805000	USD
CY2021	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1794291	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100664000	shares
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.13
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	310000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3627000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	310000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2174000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1453000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112482000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112482000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100664000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2100000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M2D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.332
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.329
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.009
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.005
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M9D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M29D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.48
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.36
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41342000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33225000	shares
CY2020Q4	cvsi	Accrued Payroll Taxes Current Employee Portion AccruedPayrollTaxesCurrentEmployeePortion	200000	USD
CY2021Q2	cvsi	Numberof Derivative Lawsuits NumberofDerivativeLawsuits	5	lawsuit
CY2021	cvsi	Numberof Derivative Lawsuits NumberofDerivativeLawsuits	4	lawsuit
CY2021	cvsi	Numberof Derivative Lawsuits NumberofDerivativeLawsuits	4	lawsuit
CY2021	us-gaap	Lease Cost LeaseCost	300000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1000000.0	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	400000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2268000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18090000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2021	us-gaap	Revenues Revenues	20048000	USD
CY2021	us-gaap	Gross Profit GrossProfit	8616000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1185000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25877000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-18446000	USD
CY2020	us-gaap	Revenues Revenues	24429000	USD
CY2020	us-gaap	Gross Profit GrossProfit	11009000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2943000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30658000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-22592000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-52000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-52000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-94000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-264000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-94000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-265000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-317000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3285000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4746000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-761000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1391000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.062
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-41000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	115000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.002
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	242000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	236000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.015
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	569000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.025
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	30000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2700000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.011
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1075000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.069
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	769000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.036
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2719000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.174
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4609000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.204
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4600000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.003
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-317000	USD
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.013
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8109000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5876000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	948000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	918000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	617000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	756000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6364000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6470000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	112000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2275000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	61000	USD
CY2021Q4	cvsi	Deferred Tax Asset Operating Lease Liabilities DeferredTaxAssetOperatingLeaseLiabilities	0	USD
CY2020Q4	cvsi	Deferred Tax Asset Operating Lease Liabilities DeferredTaxAssetOperatingLeaseLiabilities	1126000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2470000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18620000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17482000	USD
CY2021Q4	cvsi	Deferred Tax Liability Operating Lease Assets DeferredTaxLiabilityOperatingLeaseAssets	0	USD
CY2020Q4	cvsi	Deferred Tax Liability Operating Lease Assets DeferredTaxLiabilityOperatingLeaseAssets	830000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	211000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	396000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	384000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	1013000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-3000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	29000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	592000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15371000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	62000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	157000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	166000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	47000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	119000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	172000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	166000	USD

Files In Submission

Name	View Source	Status
0001510964-22-000033-index-headers.html	Edgar Link	pending
0001510964-22-000033-index.html	Edgar Link	pending
0001510964-22-000033.txt	Edgar Link	pending
0001510964-22-000033-xbrl.zip	Edgar Link	pending
a302certificationceoex3112.htm	Edgar Link	pending
a302certificationcfoex3122.htm	Edgar Link	pending
a906certificationceoex3212.htm	Edgar Link	pending
a906certificationcfoex3222.htm	Edgar Link	pending
consentex231202110k.htm	Edgar Link	pending
consentex232202110k.htm	Edgar Link	pending
cvsi-20211231.htm	Edgar Link	pending
cvsi-20211231.xsd	Edgar Link	pending
cvsi-20211231_cal.xml	Edgar Link	unprocessable
cvsi-20211231_def.xml	Edgar Link	unprocessable
cvsi-20211231_htm.xml	Edgar Link	completed
cvsi-20211231_lab.xml	Edgar Link	unprocessable
cvsi-20211231_pre.xml	Edgar Link	unprocessable
ex1040equityplanamendment.htm	Edgar Link	pending
ex42descriptionofsecurities.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVSI
CV Sciences, Inc. Stock $cvsi

2021 Q4 Form 10-K Financial Statement

#000151096422000033 Filed on April 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVSI CV Sciences, Inc. Stock $cvsi

2021 Q4 Form 10-K Financial Statement

#000151096422000033 Filed on April 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVSI
CV Sciences, Inc. Stock $cvsi